We are live on ! Find out more
BCYC

Bicycle Therapeutics

85 hedge funds and large institutions have $618M invested in Bicycle Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

24% more capital invested

Capital invested by funds: $499M → $618M (+$120M)

11% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 28

2.27% more ownership

Funds ownership: 78.48%80.75% (+2.3%)

4% less funds holding

Funds holding: 8985 (-4)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

97% less call options, than puts

Call options by funds: $171K | Put options by funds: $5.29M

Holders
85
Holders Change
-4
Holders Change %
-4.49%
% of All Funds
1.33%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
8
Increased
31
Reduced
28
Closed
12
Calls
$171K
Puts
$5.29M
Net Calls
-$5.12M
Net Calls Change
-$12.3M
Name Holding Trade Value Shares
Change
Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$71.9M
PBA
2
Paradigm Biocapital Advisors
New York
$50.7M +$3.92M +168,649 +9%
JFG
3
Jefferies Financial Group
New York
$49.7M
FLAM
4
First Light Asset Management
Minnesota
$44.4M +$24.2M +1,040,121 +149%
Morgan Stanley
5
Morgan Stanley
New York
$36.7M -$1.58M -68,182 -5%
TCM
6
Tybourne Capital Management
Hong Kong
$32.7M -$2.95M -127,011 -9%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$32.7M -$4.48M -193,054 -13%
CS
8
Candriam SCA
Luxembourg
$32.5M -$696K -29,950 -2%
SCM
9
Sio Capital Management
New York
$24.7M +$30.8K +1,324 +0.1%
AC
10
Armistice Capital
New York
$22.4M +$3.25M +140,000 +19%
BBA
11
Baker Bros. Advisors
New York
$21.5M
PCH
12
Polar Capital Holdings
United Kingdom
$19.4M -$5.81M -250,000 -25%
Verition Fund Management
13
Verition Fund Management
Connecticut
$17.3M +$2.24M +96,454 +17%
Axa
14
Axa
France
$14.1M +$2.17M +93,507 +20%
LGM
15
Logos Global Management
California
$13.3M -$5.34M -230,000 -31%
BNP Paribas Asset Management
16
BNP Paribas Asset Management
France
$13M -$238K -10,263 -2%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$12.2M -$7.53M -324,400 -40%
SCM
18
Soleus Capital Management
Connecticut
$10.5M
Nomura Holdings
19
Nomura Holdings
Japan
$10.2M +$9.29M +400,000 New
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$7.59M -$483K -20,791 -7%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$7.33M
RCMNY
22
Rubric Capital Management (New York)
New York
$5.24M
IC
23
Ikarian Capital
Texas
$5.18M -$94.7K -4,075 -2%
BlackRock
24
BlackRock
New York
$4.62M +$50.5K +2,176 +1%
PHP
25
Parkman Healthcare Partners
Connecticut
$4.4M +$569K +24,486 +17%

BCYC Hedge Fund Activity: Q2 2023 in Review

85 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q2 2023, worth a combined $618M — up 24% from $499M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of BCYC and 8 opened new positions — a net loss of 4 holders — while 28 trimmed existing stakes and 31 added.

The largest buyer was First Light Asset Management, adding an estimated $24.2M. The largest seller was Point72 Asset Management, cutting an estimated $7.53M.

  • 85 institutional investors held Bicycle Therapeutics (BCYC) as of Q2 2023, down from 89 in Q1 2023.
  • Funds reported $618M of Bicycle Therapeutics stock for Q2 2023, up 24% quarter-over-quarter.
  • 8 funds opened new Bicycle Therapeutics positions in Q2 2023 and 12 closed out, a net change of -4 holders.
  • The largest Bicycle Therapeutics buyer in Q2 2023 was First Light Asset Management, an estimated $24.2M added.
  • The largest Bicycle Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $7.53M sold.

Based on aggregated 13F filings for Q2 2023.